Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®
- Taldefgrobep is a novel myostatin inhibitor with the potential to be an important therapy for neuromuscular disorders and metabolic diseases including obesity.
- Taldefgrobep monotherapy significantly reduced fat and increased lean muscle mass in an obese mouse model; potential body composition changes relevant to individuals living with overweight and obesity.
Poster 210: Correlation Between Reduction in Total Body Weight and Change in Waist Circumference
Poster 211: Taldefgrobep Alfa Reduces Fat and Increases Muscle in an Obese Mouse Model
The poster presentations hightlight the potential benefit of taldefgrobep in the treatment of adults living with overweight and obesity and suggest anthropometric measures of central obesity, such as waist circumference or waist-to-height ratio, may be considered as effective alternative estimations of therapeutic effect.
In a mouse model of diet-induced obesity, untreated mice exhibited an increase in fat mass of 31%, while the taldefgrobep-treated mice demonstrated increases in lean mass of 25% from baseline (p≤.0.001; Figure 1) and lost 11% of their baseline fat (p≤.0.001; Figure 2) compared to vehicle (placebo) treated mice. Insulin and leptin levels were consistently lower in taldefgrobep-treated mice compared to untreated. There was no difference in food intake over time across the taldefgrobep and untreated mice, counter to what has been observed with incretin mimetics (e.g., semaglutide) which are consistently associated with a reduction in energy intake.
"The disease of obesity is a public health crisis for which alternative treatment options remain necessary. With the unprecedented amount of weight loss generated by the latest anti-obesity medications, it is important that we carefully consider the quality of resulting body composition changes, including the degree of lean muscle loss. Taldefgrobep's differentiated mechanism offers the potential for a meaningful reduction in fat mass, the primary pathogenic tissue in obesity, while increasing lean mass. These body changes are unique relative to all approved anti-obesity medications which achieve reductions in total body weight based on a composite of fat mass loss and lean muscle mass loss, the latter of which may pose important adverse long-term health consequences" said
About Taldefgrobep alfa
Taldefgrobep alfa (BHV-2000) is a fully human recombinant protein designed to specifically designed to bind to myostatin (GDF-8) and inhibit the signaling of both myostatin and activin A, both key regulators of muscle and adipose tissue. Taldefgrobep binds myostatin. The myostatin-taldefgrobep complex then acts as an Activin 2a/2b receptor antagonist. Anti-myostatin therapy has a novel mechanism of action that may reduce fat mass, increase lean mass, and improve other metabolic parameters.
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "believe", "may" and "will" and similar expressions, are intended to identify forward-looking statements. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of
Vice President, Investor Relations
View original content to download multimedia:https://www.prnewswire.com/news-releases/biohaven-presents-preclinical-data-demonstrating-taldefgrobep-alfa-reduces-fat-and-improves-lean-mass-at-the-obesity-societys-annual-meeting-obesityweek-301956902.html
|52 Week High|
|52 Week Low|
Data Provided by Refinitiv. Minimum 15 minutes delayed.